Inhibitory angiotenzin konvertujícího enzymu u dětských kardiologických pacientů – současné zkušenosti a praxe

Stáhnout PDF English version

Autoři: L. Muhammad Najih; Z. Slavík
Působiště autorů: Department of Paediatrics, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, United Kingdom
Vyšlo v časopise: Čes-slov Pediat 2020; 75 (5): 292-302.
Kategorie: Přehledový článek

Souhrn

Srdeční selhání u dětí je relativně častá a potenciálně život ohrožující komplikace různých onemocnění včetně vrozených srdečních vad a onemocnění myokardu (např. kardiomyopatie a myokarditida). Inhibitory angiotenzin konvertujícího enzymu (ACE) jsou v současnosti přijatou součástí léčby srdečního selhání v dětském věku. Capropril, enalapril, lisinopril a ramipril jsou nejčastěji užívané ACE inhibitory u dětí se srdečním onemocněním.

Revidovali jsme publikované údaje a naši institucionální praxi ve vztahu k použití ACE inhibitorů u dětí  se srdečním selháním, abychom posoudili jejich indikace, výběr vhodného léku, rozsah dávkování, bezpečnost jejich podávání, a pokud byly dosažitelné, i informace o výsledcích jejich podávání.

Ačkoliv jsou rozsáhlé randomizované studie u dětí vzácné, jsou publikované výsledky léčby ACE inhibitory u dětí se srdečním selháním povzbudivé. Doporučujeme včasný začátek léčby, odpovídající dávkování a úzké sledování pacientů k diagnostice případných nežádoucích účinků.

Klíčová slova:

pediatrie – srdeční selhání – inhibitory angiotenzin konvertujícího enzymu

Zdroje

1. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary – J Heart and Lung Transplant 2019. https://www.jhltonline.org/article/S1053-2498(14)01156-5/fulltext.

2. Marek J, Tomek V, Skovranek J, et al. Prenatal ultrasound screening of congenital heart disease in an unselected national population: a 21-year experience. Heart Br Card Soc 2011; 97 (2): 124–130.

3. Samanek M, Slavik Z, Zborilova B, et al. Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol 1989; 10 (4): 205–211.

4. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348 (17): 1647–1655.

5. Andrews RE, Fenton MJ, Ridout DA, et al. British Congenital Cardiac Association. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland. Circulation 2008; 117 (1):79–84.

6. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296 (15): 1867–1876.

7. Timberlake K, Kantor PF. Pharmacologic therapy of heart failure in children. Pharmacol Res 2011; 64 (5): 427–430.

8. Baylen BG, Johnson G, Tsang R, et al. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980; 45 (2): 305–310.

9. Hein S, Arnon E, Kostin S, Schönburg M, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107 (7): 984–991.

10. Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73 (3): 413–423.

11. Kromer EP, Riegger GA. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988; 62 (1): 161–163.

12. Stern H, Weil J, Genz T, Vogt W, et al. Captopril in children with dilated cardiomyopathy: Acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol 1990; 11 (1): 22–28.

13. Shaddy RE, Teitel DF, Brett C. Short-term hemodynamic effects of captopril in infants with congestive heart failure. Am J Dis Child 1988; 142 (1): 100–105.

14. Sluysmans T, Styns-Cailteux M, Tremouroux-Wattiez M, et al. Intravenous enalaprilat and oral enalapril in congestive heart failure secondary to ventricular septal defect in infancy. Am J Cardiol 1992; 70 (9): 959–962.

15. Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young 1992; 2 (1): 14–19.

16. Hazama K, Nakazawa M, Momma K. Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 2001; 88 (7): 801–805.

17. Schneeweiss A. Cardiovascular drugs in children: Angiotensin--converting enzyme inhibitors. Pediatr Cardiol 1988; 9 (2): 109–115.

18. Levine TB, Olivari MT, Cohn JN. Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 1984; 76 (5): 38–42.

19. Fagard R, Amery A, Reybrouck T, et al. Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients. Circulation 1979; 60 (6): 1214–1217.

20. Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting Enzyme. NEJM 2020. https://www.nejm.org/doi/full/10.1056/NEJM197907193010301.

21. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983; 67 (4): 807–816.

22. Scammell AM, Arnold R. The effect of the first dose of captopril on blood pressure in infants in heart failure. Int J Cardiol 1989; 22 (3): 377–379.

23. Rheuban KS, Carpenter MA, Ayers CA, et al. Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure. J Pediatr 1990; 117 (4): 668–670.

24. Webster MW, Neutze JM, Calder AL. Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts. Pediatr Cardiol 1992; 13 (3): 129–135.

25. Montigny M, Davignon A, Fouron JC, et al. Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. Am J Cardiol 1989; 63 (9): 631–633.

26. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987; 316 (23): 1429–1435.

27. Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293–302.

28. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100 (23): 2312–2318.

29. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 (24): 1547–1552.

30. Swedberg K, Eneroth P, Kjekshus J, et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the Consensus trial). Consensus Trial Study Group. Am J Cardiol 1990; 66 (11): 40D–45D.

31. WHO|WHO Model Lists of Essential Medicines 2020. http://www.who.int/medicines/publications/essentialmedicines/en/.

32. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol Off J Am Soc Clin Oncol 2002; 20 (23): 4517–4522.

33. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 1991; 83 (2): 523–527.

34. Leversha AM, Wilson NJ, Clarkson PM, et al. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch Dis Child 1994; 70 (1): 35–39.

35. Alehan D, Ozkutlu S. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am Heart J 1998; 135 (4): 598–603.

36. Beekman RH, Rocchini AP, Dick M, et al. Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation. Pediatrics 1984; 73 (1): 43–51.

37. Kay JD, Colan SD, Graham TP. Congestive heart failure in pediatric patients. Am Heart J 2001; 142 (5): 923–928.

38. Kantor PF, Mertens LL. Clinical practice: Heart failure in children. Part I: Clinical evaluation, diagnostic testing, and initial medical management. Eur J Pediatr 2010; 169 (3): 269–279.

39. Moorthie S, Blencowe H, Darlison MW, et al. Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. J Community Genetics 2018; 9 (4): 387–396.

40. van der Linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58 (21): 2241–2247.

41. Webster MWI, Fitzpatrick MA, Hamilton EJ, et al. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Drugs 1985; 30 (1): 74–81.

42. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child 1988; 63 (4): 360–363.

43. Captopril in treatment of infant heart failure: a preliminary report – Int J Cardiol 2020. https://www.internationaljournalofcardiology.com/article/0167-5273(87)90153-7/abstract.

44. Slipczuk L, Rafique AM, Davila CD, et al. The role of medical therapy in moderate to severe degenerative mitral regurgitation. Rev Cardiovasc Med 2016; 17 (1–2): 28–39.

45. Frenneaux M, Stewart RA, Newman CM, et al. Enalapril for severe heart failure in infancy. Arch Dis Child 1989; 64 (2): 219–223.

46. Lin M, Chiang HT, Lin SL, Chang MS, et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol 1994; 24 (4): 1046–1053.

47. Calabrò R, Pisacane C, Pacileo G, et al. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J 1999; 138: 955–961.

48. Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol 2000; 36 (1): 270–275.

49. Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353 (13): 1342–1349.

50. Gisler F, Knirsch W, Harpes P, et al. Effectiveness of angiotensin-converting enzyme inhibitors in pediatric patients with mid to severe aortic valve regurgitation. Pediatr Cardiol 2008; 29 (5): 906–909.

51. Knirsch W, Tlach L, Stambach D, et al. Angiotensin-converting enzyme inhibitors in pediatric patients with mitral valve regurgitation – case-control study and review of the literature. Congenit Heart Dis 2010; 5 (3): 278–284.

52. Hsu DT, Zak V, Mahony L, Sleeper LA, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation 2010; 122 (4): 333–340.

53. Ohnemus D, Oster ME, Gatlin S, et al. The effect of angiotensin-converting enzyme inhibitors on the rate of ascending aorta dilation in patients with bicuspid aortic valve. Congenit Heart Dis 2015; 10 (1): E1–E5.

54. Hsu DT, Pearson GD. Heart failure in children. Part I: History, etiology, and pathophysiology. Circ Heart Fail 2009; 2 (1): 63–70.

55. Bregagnollo EA, Okoshi K, Bregagnollo IF, et al. Effects of the prolonged inhibition of the angiotensin-converting enzyme on the morphological and functional characteristics of left ventricular hypertrophy in rats with persistent pressure overload. Arq Bras Cardiol 2005; 84 (3): 225–232.

56. Colan SD. Hypertrophic cardiomyopathy in childhood. Heart Fail Clin 2010; 6 (4): 433–444.

57. Denfield SW, Webber SA. Restrictive cardiomyopathy in childhood. Heart Fail Clin 2010; 6 (4): 445–452.

58. Kantor PF, Lougheed J, Dancea A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society Guidelines. Can J Cardiol 2013; 29 (12): 1535–1552.

59. Eronen M, Pesonen E, Wallgren EI, et al. Enalapril in children with congestive heart failure. Acta Paediatr Scand 1991; 80 (5): 555–558.

60. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14 (1): 9–12.

61. Kantor PF, Abraham JR, Dipchand AI, et al. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol 2010; 55 (13): 1377–1384.

62. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol Off J Am Soc Clin Oncol 2004; 22 (5): 820–828.

63. Janbabai G, Nabati M, Faghihinia M, et al. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 2017; 17 (2): 130–139.

64. Gupta V, Kumar Singh S, Agrawal V, et al. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer 2018; 65 (11): e27308.

65. Harrington JK, Richmond ME, Fein AW, et al. Two-dimensional speckle tracking echocardiography – derived strain measurements in survivors of childhood cancer on angiotensin converting enzyme inhibition or receptor blockade. Pediatr Cardiol 2018; 39 (7): 1404–1412.

66. Ohuchi H, Hasegawa S, Yasuda K, et al. Severely impaired cardiac autonomic nervous activity after the Fontan operation. Circulation 2001; 104 (13): 1513–1518.

67. Yim DLS, Jones BO, Alexander PMA, et al. Effect of anti-heart failure therapy on diastolic function in children with single-ventricle circulations. Cardiol Young 2015; 25 (7): 1293–1299.

68. Yimgang DP, Sorkin JD, Evans CF, et al. Angiotensin converting enzyme inhibitors and interstage failure in infants with hypoplastic left heart syndrome. Congenit Heart Dis 2018; 13 (4): 533–540.

69. Jefferies JL, Hoffman TM, Nelson DP. Heart failure treatment in the intensive care unit in children. Heart Fail Clin 2010; 6 (4): 531–558.

70. Tume SC, Schwartz SM, Bronicki RA. Pediatric Cardiac Intensive Care Society 2014 consensus statement: Pharmacotherapies in cardiac critical care – treatment of acute heart failure. Pediatr Crit Care Med 2016; 17 (3 Suppl 1): S16–19.

71. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18 (3): 588–599.

72. Lloyd TR, Mahoney LT, Knoedel D, et al. Orally administered enalapril for infants with congestive heart failure: a dose-finding study. J Pediatr 1989; 114 (4): 650–654.

73. Nakamura H, Ishii M, Sugimura T, et al. The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharmacol Ther 1994; 56 (2): 160–168.

74. Momma K. ACE inhibitors in pediatric patients with heart failure. Pediatr Drugs 2006; 8 (1): 55–69.

75. Ku E, McCulloch CE, Vittinghoff E, et al. Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: Focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Heart Assoc 2018; 7 (19): e009992.

76. Gantenbein MH, Bauersfeld U, Baenziger O, et al. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. J Perinat Med 2008; 36 (5): 448–452.

77. Orchard EA, Apps A, Wilson N. Use of captopril in paediatric congestive cardiac failure: early effects on blood pressure and renal function. Arch Dis Child 2010; 95 (7): 566–567.

78. Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol 2014; 35 (3): 499–506.

79. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin–angiotensin system inhibitors. Springer Link 2020. http://link-springer-com-443.webvpn.fjmu.edu.cn/article/10.1007%2Fs00431-015-2680-8.

80. Roche SL, Timberlake K, Manlhiot C, et al. Angiotensin-converting enzyme inhibitor initiation and dose uptitration in children with cardiovascular disease: A retrospective review of standard clinical practice and a prospective randomized clinical trial. J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2016. https://www.ncbi.nlm.nih.gov/pmc//articles/PMC4889193/

81. Moffett BS, Mattamal R, Ocampo EC, et al. Impact of pharmacotherapy on interstage outcomes in single ventricle infants: medication influence on interstage weight gain. Congenit Heart Dis 2011; 6 (4): 286–293.

82. Meulen M van der, Läer S, Castro C, et al. Safety of ACE inhibitors in children with heart failure. Arch Dis Child 2016; 101 (1): e1.